The UPMC Hillman Cancer Center, previously titled the University of Pittsburgh Cancer Institute, is a National Cancer Institute-designated Comprehensive Cancer Center located in the Hillman Cancer Center in the Shadyside neighborhood of Pittsburgh, Pennsylvania, United States, adjacent to UPMC Shadyside.

During the past decade, University of Pittsburgh Cancer Institute; Division of Medical Oncology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "University of Pittsburgh Cancer Institute; Division of Medical Oncology" are "Colorectal Cancer" (1 trials) and "Prostatic Neoplasms, Castration-Resistant" (1 trials). Many other conditions were trialed in "University of Pittsburgh Cancer Institute; Division of Medical Oncology" in a lesser frequency.

Most popular intervention types in "University of Pittsburgh Cancer Institute; Division of Medical Oncology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody" (1 trials), "Cobimetinib" (1 trials), "Enzalutamide" (1 trials) and "Regorafenib" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Pittsburgh Cancer Institute; Division of Medical Oncology" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of Pittsburgh Cancer Institute; Division of Medical Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in University of Pittsburgh Cancer Institute; Division of Medical Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of Pittsburgh Cancer Institute; Division of Medical Oncology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".